MiR-20a-5p (2.7-fold decrease; p = 0.038) and miR-222-3p (2.6-fold decrease; p = 0.027) were significantly decreased in women with GDM compared with controls.
In conclusion, miR-222 is a potential regulator of ERα expression in estrogen-induced insulin resistance in GDM and might be a candidate biomarker and therapeutic target for GDM.